Stay updated with breaking news from Dren Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Early data seen with acalabrutinib plus axi-cel indicate the combination’s feasibility as bridging therapy in relapsed/refractory B-cell lymphoma.
Press Release Dren Bio, Inc. (“Dren Bio” or the “Company”) a clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune and other serious diseases, today announced the expansion of its leadership team with the appointment of Amit…
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
- Momentum continues to build for Dren Bio after successfully forming highly experienced senior leadership team and earlier this year announcing research collaboration and license deal with Pfizer -